Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imagion Biosystems Ltd. ( (AU:IBX) ) has issued an announcement.
Imagion Biosystems has successfully completed the settlement of Tranche 2 of its $3.5 million Placement, raising $2.85 million in funds. These proceeds will be used to advance the company’s MagSense® imaging technology, specifically targeting the HER2 breast cancer indication, and to initiate studies for prostate and ovarian cancer. The company plans to commence a Phase 2 clinical trial for HER2 breast cancer, with objectives including the submission of an IND application to the FDA, completion of drug manufacturing, filing of new IP applications, and collaborations with MRI experts to enhance their imaging platform.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is a healthcare company focused on the early detection of cancer using its proprietary MagSense® imaging technology. The company is primarily engaged in advancing imaging solutions for cancer indications, including HER2 breast cancer, prostate cancer, and ovarian cancer.
Average Trading Volume: 10,350,735
Technical Sentiment Signal: Buy
Current Market Cap: A$10.1M
Find detailed analytics on IBX stock on TipRanks’ Stock Analysis page.